Home / Conditions / Chronic Fatigue Synd
Chronic Fatigue Synd: when insurers say no, reviewers often say yes
In 24 published external-review decisions involving chronic fatigue synd, independent physician reviewers overturned the insurer’s denial 16.7% of the time.
Published decisions
24
2001–2026
Overturned
16.7%
4 denials reversed
Most-fought treatments for chronic fatigue synd
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| OON Referral | 3 | 33.3% |
| Non-FDA Approved Use | 3 | 33.3% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 16 | 25% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 8 | 0% |
Typical time to a decision
20 days
Most land between 14 and 21 days
Handled as urgent
16.7%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for immune globulin therapy, Gammagard liquid 500 mg.Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a very difficult-to-diagnose disease. The most pronounced presentation is unexplained persistent severe fatigue. The authors of a study determined that there was a lower quality of life and a higher prevalence of fatigue among those with immunoglobulin subset deficiencies. Intravenous immunoglobulin therapy has been tried in patients with chronic fatigue syndrome and the consensus is that the therapy has resulted in significant benefit. Further, a recent study suggests that the benefit of intravenous immunoglobulin G (IV IgG) infusions to treat CFS/ME may have been underestimated.
The patient is a 53-year-old female with a history of chronic fatigue syndrome, fibromyalgia, obstructive sleep apnea, arthritis, and chronic headaches. She has been tried on all anti-inflammatories, Risperdal, Zonegran, Prozac, and Diazepam without benefit. The patient’s current medication regimen includes Welbutrin, Effexor, Fiorinal, Ambien, Soma, and Nortriptyline. She continues to have fatigue and constant pain. The patient also is participating in a chronic fatigue group. Her primary care physician has recommended Provigil to help improve the patient’s energy. The Health Plan has denied authorization and coverage for Provigil on the basis it is not medically necessary for treatment of the patient’s medical condition. Based upon the submitted medical records, it does not appear the patient is currently responding to most of the medications that she has tried in the past.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
The enrollee is requesting authorization and coverage for the treatment plan by provider, to include the medications: Valtrex (valacyclovir) 500mg three (3) times daily, Abilify (aripiprazole) 1.5mg daily, low-dose naltrexone 4.5mg daily, and Plaquenil (hydroxychloroquine) 300mg daily. The enrollee has chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease. She complains of profound fatigue, un-improved with bed rest and worsened by physical or mental activity. She has various non-specific symptoms, including weakness, muscle pain, impaired memory and/or mental concentration, insomnia, and post-exertional fatigue, lasting more than 24 hours. The enrollee has been on Valtrex, Plaquenil, Naltrexone, and Abilify.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for IVIG therapy.The submitted clinical documentation does not support that IVIG therapy is medically necessary for the patient. There are no visit notes demonstrating how diagnoses of mast cell activation syndrome (MCAS), Ehlers-Danlos syndrome or postural hypotension syndrome (POTS) were made. All of the patient’s submitted mast cell studies were normal and the records fail to demonstrate evidence of mast cell activation syndrome.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for chronic fatigue synd was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.